Biospring Management, LLC
SEC exempt reporting adviser (venture capital exemption).
- Website
- https://www.biospring.com
- HQ
- NY
Biospring Management, LLC partners with technology-enabled pharma services businesses that are EBITDA-positive and driving innovation in manufacturing and clinical trial services. The firm lists Michelle Detwiler, Jennifer Lum, Socrates Zacharias, Jordan Feyko, and Matt McBryan on its team. Cedar Health Research is one of its portfolio companies.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Growth | Not enough dated deals | None |
| Sectors | Biotech | Not enough dated deals | None |
| Regions | Not stated | Not enough dated deals | None |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2019 | 1 | Fintech |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Biospring Partners CHR, LP Biospring partners with technology-enabled, EBITDA-positive pharma services businesses in manufacturing and clinical trial services. It backs outsourced complex biomanufacturing, clinical trial site networks, digitized clinical pathology and lab procurement platforms, and growth investments such as Serán Bioscience's CDMO expansion. Inferred from the firm's website | 2026 | $5M (Form D) | Open, writing first checks |
| BIOSPRING PARTNERS 2, LP Biospring partners with technology-enabled, EBITDA-positive pharma services businesses in manufacturing and clinical trial services. It backs outsourced complex biomanufacturing, clinical trial site networks, digitized clinical pathology and lab procurement platforms, and growth investments such as Serán Bioscience's CDMO expansion. Inferred from the firm's website | 2025 | $10M (Form D) | Open, writing first checks |
| Biospring Partners Fund II, L.P. Biospring partners with technology-enabled, EBITDA-positive pharma services businesses in manufacturing and clinical trial services. It backs outsourced complex biomanufacturing, clinical trial site networks, digitized clinical pathology and lab procurement platforms, and growth investments such as Serán Bioscience's CDMO expansion. Inferred from the firm's website | approx. 2024 | $350M (Form D) | Open, writing first checks |
| Biospring Partners ABZ Fund V, L.P. Biospring partners with technology-enabled, EBITDA-positive pharma services businesses in manufacturing and clinical trial services. It backs outsourced complex biomanufacturing, clinical trial site networks, digitized clinical pathology and lab procurement platforms, and growth investments such as Serán Bioscience's CDMO expansion. Inferred from the firm's website | 2022 | $16.5M to $21.17M (Form D and SEC adviser filing) | Late investment period |
| Biospring Partners ABZ Fund, L.P. | 2020 | $12.1M to $23.16M (Form D and SEC adviser filing) | Follow-ons only |
| Biospring Partners Fund, L.P. | 2020 | $225.38M to $229.44M (Form D and SEC adviser filing) | Follow-ons only |
03 · People across funds
- Jeff Bullock, CFO/CCO
Biospring Partners CHR, LP (Named on Form D)
- Jennifer Lum, Managing Partner
Biospring Partners CHR, LP (Team); BIOSPRING PARTNERS 2, LP (Team); Biospring Partners Fund II, L.P. (Named on Form D); Biospring Partners ABZ Fund V, L.P. (Named on Form D); Biospring Partners ABZ Fund, L.P. (Named on Form D); Biospring Partners Fund, L.P. (Named on Form D)
- Michelle Detwiler, Managing Partner
Biospring Partners CHR, LP (Named on Form D); BIOSPRING PARTNERS 2, LP (Named on Form D); Biospring Partners Fund II, L.P. (Named on Form D)
- MICHELLE DIPP, Manager of the General Partner of the Issuer
Biospring Partners ABZ Fund V, L.P. (Named on Form D); Biospring Partners ABZ Fund, L.P. (Named on Form D); Biospring Partners Fund, L.P. (Named on Form D)
- Jordan Feyko, Vice President
Biospring Partners CHR, LP (Team); BIOSPRING PARTNERS 2, LP (Team); Biospring Partners Fund II, L.P. (Team); Biospring Partners ABZ Fund V, L.P. (Team); Biospring Partners ABZ Fund, L.P. (Team); Biospring Partners Fund, L.P. (Team)
- Matt McBryan, Associate
Biospring Partners CHR, LP (Team); BIOSPRING PARTNERS 2, LP (Team); Biospring Partners Fund II, L.P. (Team); Biospring Partners ABZ Fund V, L.P. (Team); Biospring Partners ABZ Fund, L.P. (Team); Biospring Partners Fund, L.P. (Team)
- Michelle Detwiler MD, PhD, Managing Partner
Biospring Partners CHR, LP (Team); BIOSPRING PARTNERS 2, LP (Team); Biospring Partners Fund II, L.P. (Team); Biospring Partners ABZ Fund V, L.P. (Team); Biospring Partners ABZ Fund, L.P. (Team); Biospring Partners Fund, L.P. (Team)
- Socrates Zacharias, Principal
Biospring Partners CHR, LP (Team); BIOSPRING PARTNERS 2, LP (Team); Biospring Partners Fund II, L.P. (Team); Biospring Partners ABZ Fund V, L.P. (Team); Biospring Partners ABZ Fund, L.P. (Team); Biospring Partners Fund, L.P. (Team)
- Chad Hooper, Operating Partner
On the team page, not linked to a fund
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://www.biospring.com
- https://biospring.com/team
- https://biospring.com/
- https://biospring.com/biospring-news/biospring-hosts-webinar-on-community-focused-clinical-research-with-cedar-health-and-amgen?hsLang=en
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026